Asthma| Treatment Algorithms | Claims Data Analysis | US | 2018
Asthma pharmacotherapy has two main goals: address underlying airway inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goals—maintenance therapy (e.g., a LABA/ICS such as GlaxoSmithKline’s Advair or AstraZeneca’s Symbicort) and rescue therapy (e.g., a SABA such as albuterol)—and most asthma patients receive more than one drug to treat their condition. Multiple well-established agents have been available for both maintenance and rescue treatment, but in the past two years, the asthma treatment landscape expanded even more with the approvals of the first branded-generic LABA/ICSFDC (i.e., Teva’s AirDuo and its generic), the first LAMA (i.e., BoehringerIngelheim’s Spiriva), and two novel biologics (i.e., GlaxoSmithKline’s Nucala and Teva’s Cinqair). These agents have expanded physicians’ treatment arsenal and fueled increasing competition in the asthma therapy market.
What patient share do key therapies and brands garner by line of therapy in newly diagnosed asthma patients? What are the quarterly trends in prescribing among recentlytreated and newly diagnosed asthma patients?
How have newer inhaled asthma therapies, such as Breo, Spiriva, Nucala, and Cinqair, been integrated into the treatment algorithm?
What proportion of asthma patients receive drug therapy within 365 days of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
What percentage of asthma patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with asthma?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use in different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.